Company
Kyverna Therapeutics
Kyverna Therapeutics has 5 drugs tracked on RxWires: 1 in Phase 2/3, 1 in Phase 2, 2 in Phase 1/2, 1 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Standard lymphodepletion regimen | Phase 2/3 | Myasthenia Gravis |
| KYV-101 | Phase 2 | Multiple Sclerosis, Primary Progressive |
| KYV101 | Phase 1/2 | Rheumatoid Arthritis |
| KYV-101 anti-CD19 CAR-T cell therapy | Phase 1/2 | Lupus Nephritis |
| KYV-101 (Biological) - 0.33 ×10^8 cells | Phase 1 | Progressive Multiple Sclerosis |
Latest
- kyverna therapeutics filed 8-K
- kyverna therapeutics filed 8-K
- kyverna therapeutics filed 8-K
- kyverna therapeutics filed 8-K
- kyverna therapeutics filed 8-K
Follow Kyverna Therapeutics on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.